- A Short Classification Of Leukemia Cells By : Groshan Fabiola
In the bone marrow are produced the leukemia cells which are abnormal and immature. These cells are classified in two types- lymphoid leukemia cells and myeloid leukemia cells. - Diagnosing Lymphoma By : Groshan Fabiola
To diagnose a lymphoma case if very difficult because many of the lymphoma symptoms are similar to those of other medical conditions. However, based on the symptoms, you might suspect a lymphoma case and go see a doctor, where you will have a physical examination. - Lymph Nodes Cancer By : Sven Ullmann
Lymph node cancer or lymphoma is a cancer that accounts for approximately five percent of all cancers. It predominantly effects males but is not exclusive to men. - Who Does Lymphoma Affect? By : Jeremy Parker
Lymphoma is a form of cancer that affects a specific type of cell called the lymphocytes. These tiny but incredibly important cells are classed as cells of the immune system and so when they begin to mutate and become cancerous the immune response to- - What Exactly is Lymphoma? By : Jeremy Parker
Lymphoma is not a single disease, it is in fact a group of diseases in which the cells of the immune system become cancerous and begin to divide and multiply in an uncontrolled manner in a lymph node. Initially a single lymph node may be affected however - What is Leukemia? By : Groshan Fabiola
Today, one of the most dangerous and incurable condition seems to be cancer. It has no actual cure for mostly of the tissues it affects, especially when it reaches vital organs such as heart, lungs or blood. - Characteristics of Hodgkin's Lymphoma By : Groshan Fabiola
Lymphomas are the cancer of the lymphoid tissue, so Hodgkin's disease which is a type of lymphoma, is also a cancer of this tissue. Lymphoid tissue is part of the lymphatic system which is a major component of the immune defense system. - Appropriate Treatment - Non-Hodgkin's Lymphoma's Cure? By : Groshan Fabiola
How can cancer be treated? This is the most frequent question in medical research. New treatments are tested on patients under close observation of medical squads. It's hard work for researchers who have to determine an optimal dose of the treatment for each patient - Statistic Data on Leukemia By : Groshan Fabiola
Leukemia is the blood cancer form and originates in a malfunctioning bone marrow that tends to produce abnormal red and white cells in an increased rate. The most important four types of Leukemia are the acute and chronic myelogenous leukemia - Leukemia-Lymphoma Cancer And Himalayan Goji Juice Shows Positive Results in Cancer Research By : Gavin Tunnell
Inhibition the growth of human leukemia cells by Lycium barbarum polysaccharide. Observation of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in the treatment of 75 cancer patients. - How Can non-Hodgkin's Lymphoma Be Detected? By : Jeremy Parker
Non-Hodgkin's lymphoma is a term that describes a group of over 30 subtypes of lymphoma, each of which grows and differentiates at a different rate and so responds differently to treatment. Even though the subtypes are all individual they exhibit very similar symptoms and - Keeping the Faith: Turning to Religion When Diagnosed with Lymphoma By : Jeremy Parker
Being diagnosed with a potentially life threatening medical condition, such as lymphoma, can often cause a person to revaluate their life and many find religion in the process. While some return to a lapsed religion, others find - The Target Of The Treatment In Non-Hodgkin's Lymphoma By : Groshan Fabiola
Nowadays, cancer is one of the most serious problems in medicine. Specialists try to discover new treatments. - Signs-Symptoms And Life-Expectation In Acute Leukemia By : Groshan Fabiola
First occurring signs in the development of acute forms of leukemia are bruising and bleedings caused by the decreased number of platelets, fatigue and pales due to the anemia caused by insufficient red blood cells, reoccurring infections and late healing due to abnormal number and function of white blood cells. - Mantle Cell Lymphoma-An Indolent Or An Aggressive Disease? By : Groshan Fabiola
Mantle cell lymphoma is a non-Hodgkin's lymphoma type of cancer and it represents affection of the lymphatic system. - Lymphoma-A Consequence Of Rheumatoid Arthritis By : Groshan Fabiola
RA, rheumatoid arthritis, is a disease that affects the cells around the joints. Rheumatoid arthritis involves a lot of pain but in the advanced stages can also mean immobility because in time, the tissues around the joints are deteriorating. - Gleevec Therapy Method For Leukemia By : Groshan Fabiola
The therapy of chronic myeloid leukemia with Gleevec (Imatinib mesylate) began to be used in patients in 2001. - Treatment Options for Mantle Cell Lymphoma By : Groshan Fabiola
A rare form of the Non-Hodgkin disease is the Mantle cell lymphoma. This disease is quite dangerous because its tumor grows very fast and ends up affecting most of the organs. - Mantle Cell Lymphoma By : Groshan Fabiola
Examined under the microscope, the Mantle cell lymphoma appears as an expansion of the mantle zone area of the lymph nodes. It is represented by a homogenous population - Hodgkin's Lymphoma, The White Cell Cancer By : Groshan Fabiola
Many types of cancer are known our days, but Hodgkin’s disease is one that can be cured if the medical advice and treatment is followed properly. Hodgkin’s disease, - Decisions Upon Leukemia Treatment By : Groshan Fabiola
Very often persons without any disease symptoms whatsoever are diagnosed with chronic myeloid Leukemia during a routine blood testing. Unlike the acute forms of Leukemia - Acute Lymphocytic Leukemia in Children By : Groshan Fabiola
Cancer in any of its forms is known to the society as a condition of adults or elder persons; still it can occur at any age even during the care-free childhood period. - General aspects of Mantle Cell Lymphoma By : Groshan Fabiola
Mantle cell lymphoma (MCL) takes part to a group of cancers which affect the lymphatic system. This diseases are known as non-Hodgkin's lymphomas. The immune system - Lymphoma: Who is Susceptible? By : Jeremy Parker
Lymphoma, as with virtually every other form of cancer, can strike anybody at any time during their life however some groups are more susceptible to the disease than others. Studies around the world have shown that age, gender and geographical location affect whether - Treating Non-Hodgkin lymphoma By : Groshan Fabiola
Until now, patients suffering of Non-Hodgkin lymphoma were treated with chemotherapy and radiation. In some of the cases the treatment was useful but in most patients treatment was very toxic and did not lead to a cure - How To Stop Lymphoma Ruling Your Life By : Jeremy Parker
Being diagnosed with lymphoma will be incredibly stressful and when treatment starts it may be that you are at the hospital five days a week for up to eight weeks at a time. Obviously this is going to put immense pressure on both you and your family and so the- - Childhood Lymphoma By : Alison Cole
The term childhood lymphoma refers to cancers that originate in the body's lymphatic tissues during childhood and include the lymph nodes, thymus, spleen, tonsils, adenoids, and bone marrow, as well as the lymph vessels that attach them. Although there are many types of cancer that eventually spread to parts of the lymphatic system, lymphomas are distinctive because they originate there. Statistics report that there are about 1,700 children below 20 years of age who are diagnosed with lymphoma each year in the United States. Childhood lymphomas are divided into two basic categories, Hodgkin's disease and non-Hodgkin's lymphoma, based on the appearance of their cancerous cells, and is the third most common type of cancer in children. - Lymphoplasmacytic Disorders By : Alison Cole
Lymphoplasmacytic disorder is a disease that affects the lymphoplasmacyte cells that produce monoclonal light chained immunoglobulins, which are part of the immune system. - Tonsil Lymphoma By : Alison Cole
Lymphoma is a type of cancer that originates in lymphocytes, which are cells that circulate in the lymphatic system. When this cancer affects the tonsils that are part of the lymphatic system, then it is termed as tonsil lymphoma. - Types of Lymphoma and Their Characteristics By : Groshan Fabiola
Lymphoma refers to a form of tumor caused by the immune system, involving abnormal activity of lymphocytes, body cells that belong to the lymphatic system. - Ocular Lymphoma – A Major Indicator of Brain Involvement in Patients with Non-Hodgkin's Lymphoma By : Groshan Fabiola
Ocular lymphoma, also referred to as intraocular large cell lymphoma, is a subtype of Non-Hodgkin’s Lymphoma that primarily affects the central nervous system - Aspartame and the Increased Risks of Lymphoma Cancer By : Groshan Fabiola
According to the findings of a recent study conducted by the Cancer Research Center of the European Foundation of Oncology and Environmental Sciences in Bologna, Italy, the frequent use of aspartame considerably increases the risks of developing lymphoma cancers - Different Treatments to Treat Mantle Cell Lymphoma By : Groshan Fabiola
Lymphoma is a serious affection which affects different parts of the body and usually occurs in many forms. One of the most severe form of lymphoma is known as Mantle cell - The Best Lymphoma Classification By : Groshan Fabiola
Lymphoma is a severe type of cancer which arise from white blood cells called lymphocytes. In addition to this, white blood cells help the body by fighting against bacteria - Children's Hospital Researcher Leads Multipronged Attack On Infant Leukemia By : Leukemia News
While survival rates for childhood leukemia have dramatically improved over the past 30 years, infants with this blood cancer continue to face difficult odds. Infant leukemia resists treatments such as chemotherapy and stem cell transplants that may be effective in older children, and infants are especially vulnerable to treatment side effects. - Genta Provides Update On Analysis Of Phase 3 Trial Of Genasense(R) In Older Patients With Acute By : Leukemia News
Genta Incorporated (Nasdaq: GNTA) today announced that the Company has been notified of preliminary results from a randomized Phase 3 trial of chemotherapy with or without Genasense(R) (oblimersen sodium) Injection that was conducted in older, previously untreated patients with acute myelogenous leukemia. - FDA Approves VELCADE(R) (Bortezomib) For Injection For Aggressive Form Of Non-Hodgkin's Lymphoma By : Leukemia News
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of VELCADE for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. - Gleevec(R) Demonstrates Highest Five-Year Overall Survival Rate In History Of Treatment For Patients By : Leukemia News
Data published today in the New England Journal of Medicine underpinned Gleevec(R) (imatinib mesylate) tablets as a durable and well-tolerated long-term therapy for newly diagnosed adult patients with a form of blood cancer known as Philadelphia chromosome- positive (Ph+) chronic myeloid leukemia (CML) - Genetic Susceptibility And Inherited Tendencies In The Occurrence And Treatment Of Blood Cancer By : Leukemia News
People who are born with or develop specific genetic mutations may be prone to certain blood cancers, and some inherited genes associated with cancer apparently cluster within families. - New Research Helps Patients With Blood Cancers By : Leukemia News
A NHMRC funded study by the International Program of Psycho-Social Health Research (IPP-SHR) is leading the way to ensure that patients diagnosed with a haematological disorder (blood-related cancer) receive access to palliative care services. - Study Showed Epratuzumab In Combination With Rituximab And Chemotherapy Is Safe, Tolerable, And Acti By : Leukemia News
Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies, today reported that adding epratuzumab to rituximab and combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) to treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) produced promising results. - Favrille To Report Data From Phase 2 And Phase 3 Clinical Trials Of FavId At American Society Of Hem By : Leukemia News
Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that data from its Phase 2 and Phase 3 clinical trials of FavId(R) following Rituxan(R) induction therapy in patients with follicular B-cell non-Hodgkin's lymphoma (NHL) will be reported at the upcoming American Society of Hematology (ASH) Annual Meeting in Orlando. - New Hope For Patients With Chronic Lymphocytic Leukemia By : Leukemia News
Patients treated with lenalidomide for relapsed chronic lymphocytic leukemia (CLL) or disease that no longer responds to chemotherapy have experienced a major response to therapy, according to a phase II study conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI). The results are published in the December 1 issue of the Journal of Clinical Oncology. - Abbott Introduces CE-Marked DNA Tests In Europe For The Detection Of Chromosomal Abnormalities Assoc By : Leukemia News
Abbott Molecular today announced that it has introduced six CE-marked DNA tests in Europe for use by diagnostic laboratories in identifying chromosomal abnormalities associated with certain forms of leukemia, a cancer of the white blood cells originating in the bone marrow. - Genzyme Begins Phase 2 Pivotal Study Of Clolar(R) In Adult Acute Myelogenous Leukemia By : Leukemia News
Genzyme Corporation (Nasdaq: GENZ) announced today that it has begun treating patients in a phase 2 clinical trial examining the safety and effectiveness of Clolar(R) (clofarabine) in previously untreated, older adult patients with acute myelogenous leukemia (AML) who are unlikely to benefit from standard induction therapy. - Scientific Breakthrough In The Screening & Treatment Of Canine Lymphoma Cancer Is A World First By : Leukemia News
Canine lymphoma is one of the most prolific cancers in the dog population. It accounts for more than 20 percent of all cancers and in certain high risk breeds this figure could be considerably higher. - Leukemia By : Steve John Cowan
The most dangerous feature of leukemia is that is attacks the blood which then has access to all of the bodies other organs, including the all brain, heart, kidneys and liver - BioCryst's Fodosine(TM) Granted Orphan Status In Europe By : Leukemia News
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that following the favorable opinion of the European Committee for Orphan Medicinal Products (COMP) - What Is Lymphoma? By : Jeff Kimball
Are you dealing with the Lymphoma? Maybe a friend or loved one has been diagnosed with Lymphoma cancer. This article will give you the basics of what Lymphoma is and lead you to the Lymphoma Cancer Information Portal where you can learn more about this disease. - 'Tribbles' Protein Implicated In Common And Aggressive Form Of Leukemia By : Leukemia News
Researchers at the University of Pennsylvania School of Medicine have identified a new protein associated with acute myelogenous leukemia (AML). Several lines of evidence point to a protein called Tribbles, named after the furry creatures that took over the starship Enterprise in the original Star Trek series. Tribbles was first described in fruit flies. - Targeting Leukemic Stem Cells By BCL-2 Inhibition By : Leukemia News
Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers - The Leukemia & Lymphoma Society, Ensemble Discovery Corp. Initiate Research Program To Apply By : Leukemia News
Marking the launch of its new initiative to accelerate the development of blood cancer therapies, The Leukemia & Lymphoma Society today announced a collaboration with Ensemble Discovery Corp. of Cambridge, MA. - Findings On The Mechanisms That Cause Resistance To Treatment May Lead To Better Targeted Therapies By : Leukemia News
Research to be published in the journal Blood and posted today on the journal's Web site, suggest that defects in the way blood cells process critical messages are what make patients with acute myelogenous leukemia (AML) resistant to therapy. That discovery may suggest new ways to treat patients with AML. - Cells Identified That Make Relapse Inevitable In Acute Lymphoblastic Leukemia By : Leukemia News
In "Dr Jekyll and Mr Hyde" Robert Louis Stevenson wrote about the good and evil sides of the same person; now scientists in Australia have discovered that in acute lymphoblastic leukaemia (ALL) there are Dr Jekyll and Mr Hyde cells - "good" and "evil" clones of the same type of ALL cell. - Vion Pharmaceuticals Reaches Midpoint Of Patient Accrual To Cloretazine(R) (VNP40101M) Phase III By : Leukemia News
Vion Pharmaceuticals, Inc. (Nasdaq: VION) today announced that it had accrued 210 patients to the Phase III trial of its lead anticancer agent Cloretazine(R) (VNP40101M). The trial is evaluating Cloretazine(R)(VNP40101M) in combination with cytarabine for the treatment of relapsed acute myelogenous leukemia (AML). - Favrille Announces Interim Analysis Of Secondary Endpoint From Pivotal Phase 3 Clinical Trial By : Leukemia News
Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that the Data Monitoring Committee (DMC) completed its prospectively planned interim analysis of a secondary endpoint in the first 233 patients enrolled in the Company's ongoing pivotal, placebo-controlled Phase 3 clinical trial of FavId(R) following Rituxan(R) induction therapy in patients with follicular B- cell non-Hodgkin's lymphoma (NHL) - Cholesterol Screening A Cost-effective Procedure To Extend Life In Hodgkin's Disease Survivors By : Leukemia News
Hodgkin's lymphoma survivors who have lipid screening every five years to detect high cholesterol will live a half year longer than patients who don't have the screening and the intervention is cost-effective, according to a study presented November 8, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia - Researchers Identify Cells That Make Relapse Inevitable After Treatment For Acute Lymphoblastic By : Leukemia News
Prague, Czech Republic: In "Dr Jekyll and Mr Hyde" Robert Louis Stevenson wrote about the good and evil sides of the same person; now scientists in Australia have discovered that in acute lymphoblastic leukaemia (ALL) there are Dr Jekyll and Mr Hyde cells - "good" and "evil" clones of the same type of ALL cell. - Value Of 'Helper' Compound In Treating Some Leukemias By : Leukemia News
The abberant Philadelphia chromosome is not a problem local to Philadelphia, but that's where researchers discovered the genetic mutation that's the root cause of some leukemias, including chronic myeloid leukemia (CML) and B-cell acute lymphoblastic leukemia (B-ALL). - Cholesterol Screening A Cost-Effective Procedure To Extend Life In Hodgkin's Survivors By : Leukemia News
Hodgkin's lymphoma survivors who have lipid screening every five years to detect high cholesterol will live a half year longer than patients who don't have the screening and the intervention is cost-effective, according to a study presented November 8, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia. - Updated Safety Analysis Of Allos Therapeutics Phase 1/2 Study Of PDX In Patients With Aggressive By : Leukemia News
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the presentation of updated safety results from its Phase 1/2 trial of PDX (pralatrexate) in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease. - Deakin University Discovery Could Lead To New Leukaemia Treatments By : Leukemia News
Deakin University scientists have identified a protein that could hold the key to new leukaemia treatments. - Allos Therapeutics Announces Presentation Of Updated Results From Phase 1/2 Trial Of PDX In Patients By : Leukemia News
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that updated results from a Phase 1/2 study evaluating the Company's novel antifolate PDX (pralatrexate) in patients with relapsed or refractory non-Hodgkin's lymphoma and Hodgkin's disease have been accepted for presentation at the American Society of Hematology's 48th Annual Meeting, to be held December 9 - 12 in Orlando. - New Analyses From Phase 3 Trial In CLL Identify Relapsed Patients Who Maximally Benefit By : Leukemia News
Genta Incorporated (Nasdaq: GNTA) announced the presentation of new analyses from the Company's randomized Phase 3 trial of Genasense(R) (oblimersen sodium) Injection in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). - Promising Target For New Atherosclerosis Therapies Linked To Leukemia By : Leukemia News
In recent years, scientists studying inflammation and atherosclerosis have seen their respective fields converging. Inflammation is an aspect of the immune response to injury and disease; atherosclerosis, with its characteristic lesions in the blood vessel walls, underlies most cardiovascular disease, including heart attacks and strokes. - Promising Target For New Atherosclerosis Therapies Linked To Leukemia By : Leukemia News
In recent years, scientists studying inflammation and atherosclerosis have seen their respective fields converging. Inflammation is an aspect of the immune response to injury and disease; atherosclerosis, with its characteristic lesions in the blood vessel walls, underlies most cardiovascular disease, including heart attacks and strokes. - Berlex Oncology Evaluating Combination Therapy For Common Form Of Non-Hodgkin's Lymphoma By : Leukemia News
Berlex Oncology, a business unit of Berlex Laboratories, a U.S. affiliate of Schering AG, Germany (FSE: SCH; NYSE: SHR), today announced that a national clinical study is underway investigating a new approach to treating follicular B-cell lymphoma, a sub- type of non-Hodgkin's lymphoma (NHL). NHL is the fifth most common form of cancer in the United States, with more than 56,000 new cases diagnosed each year. - Patient Accrual Completed Into Phase 3 Trial Of Genasense(R) In Patients With Acute Myeloid Leukemia By : Leukemia News
Genta Incorporated (Nasdaq: GNTA) announced that target patient accrual has been completed into a randomized Phase 3 trial of Genasense plus chemotherapy in previously untreated patients with acute myeloid leukemia (AML). The trial was conducted by the Cancer and Leukemia Group B (CALGB), the largest U.S. oncology cooperative group, and was sponsored by the National Cancer Institute (NCI). - FDA Extends Review Period For Genasense(R) New Drug Application In Chronic Lymphocytic Leukemia By : Leukemia News
Genta Incorporated (Nasdaq: GNTA) announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it has extended the review period for the currently pending New Drug Application (NDA) for Genasense(R) (oblimersen sodium) Injection plus chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). - Thousands Of Myeloma Patients Lose Their Last Hope After Not-so-NICE Final Ruling On Velcade, UK By : Leukemia News
Too expensive was the reason given by the National Institute for Health and Clinical Excellence (NICE) today for rejecting a vital treatment for the bone marrow cancer, myeloma, despite it being the only treatment to be licensed for patients in over ten years. - Symptoms of Chronic and Acute Leukemia By : Groshan Fabiola
Discovering leukemia while it is still in an early phase is crucial in its treatment because when the disease advances it starts to spread in the whole body and it's much harder to be treated. - New Hope For Children When Leukemia Treatment Fails By : Leukemia News
Clinicians at St. Jude Children's Research Hospital have successfully demonstrated an improved technique for blood stem cell transplantations in children that shows promise for those most likely to fail standard treatment for leukemia. - Chronic Leukemia - A Less Dangerous Cancer, But Harder To Treat By : Groshan Fabiola
Leukemia is a dangerous form of cancer, and it affects thousands of people every year. It affects the white blood cells. The body loses control of the quantity - Child Leukemia - Generalities, Symptoms and Treatment By : Groshan Fabiola
Leukemia interferes with the body's production of white blood cells. These cells are supposed to fight infections with viruses or bacteria, and when someone has - Potential Target For Leukemia Treatment: Cincinnati Children's Researchers Publish Findings By : Leukemia News
Cincinnati Children's Hospital Medical Center today announced the publication of pioneering research identifying the crucial role and novel mechanism of action of the protein RhoH GTPase in the development and activation of cells critical to the immune system. - The Leukemia & Lymphoma Society Launches Program To Ease The Return To School For Children By : Leukemia News
Each year approximately 9,000 children and teenagers are diagnosed with cancer in the United States, with leukemia representing more than 30% of these cases. Thanks to research advances, the survival rate for the most common pediatric cancer, acute lymphocytic leukemia (ALL), has improved from a dismal 4 percent in the 1960s to more than 85 percent today. However, for children who survive cancer, the challenges continue long after the treatments are over. - Cincinnati Children's Researchers Publish Findings On Potential Target For Leukemia Treatment By : Leukemia News
Cincinnati Children's Hospital Medical Center today announced the publication of pioneering research identifying the crucial role and novel mechanism of action of the protein RhoH GTPase in the development and activation of cells critical to the immune system. The findings, along with other studies, suggest that RhoH GTPase may provide a target for therapeutic intervention in some types of leukemia. - Three Molecular Triggers Threaten Leukemia Patients By : Leukemia News
The road to better treatment for the most common form of adult leukemia will require blocking multiple molecular pathways that fuel the disease, researchers at The University of Texas M. D. Anderson Cancer Center report in the Oct. 1 edition of the journal Blood. - Journal Of Clinical Oncology Publishes Final Study Results Of VELCADE(R) (Bortezomib) For Injection By : Leukemia News
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that the Journal of Clinical Oncology has published the final results of the PINNACLE trial, one of the largest multi-center studies ever done in the setting of relapsed mantle cell lymphoma (MCL). - Genta Receives Special Protocol Assessment From FDA For Randomized Trial Of Genasense(R) By : Leukemia News
Genta Incorporated (Nasdaq: GNTA) announced that the Company's proposal for a randomized trial of Genasense(R) (oblimersen sodium) Injection in patients with chronic lymphocytic leukemia (CLL) has completed Special Protocol Assessment (SPA) by the Food and Drug Administration (FDA). - NCCN Updates Chronic Myelogenous Leukemia Guidelines By : Cancer News
The National Comprehensive Cancer Network (NCCN) is proud to announce several new updates to the NCCN Clinical Practice Guidelines in OncologyTM for Chronic Myelogenous Leukemia (CML). These changes highlight leading developments in the treatment of CML and represent the recognized standard for clinical policy in oncology in both the community and the academic practice settings. - Allos Therapeutics Receives FDA Fast Track Designation For PDX For The Treatment Of T-cell Lymphoma By : Leukemia News
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the Company's unique next-generation antifolate PDX (pralatrexate) for the treatment of patients with T-cell lymphoma. - Cellgate Initiates Innovative Phase Ib Clinical Study Of Anti-proliferative Agent, CGC-11047 By : Leukemia News
Cellgate Inc., a company developing novel anti-proliferative drugs to combat cancer and other diseases, today announced the initiation of a Phase Ib clinical study of CGC-11047 in patients with advanced solid tumor malignancies or lymphomas. - NICE Recommends Rituximab For The First Line Treatment Of Follicular Lymphoma, UK By : Leukemia News
NICE has issued guidance to the NHS in England in Wales recommending rituximab, within its licensed indications, (that is, in combination with cyclophosphamide, vincristine and prednisolone - or CVP) as an option for the treatment of patients with symptomatic stage III and IV follicular lymphoma who have previously been untreated. - FDA Approves Two New Indications For Rituxan(R) In Patients With Non-Hodgkin's Lymphoma By : Leukemia News
Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved, after a Priority Review, two additional uses for Rituxan(R) (Rituximab) for patients with CD20-positive, B-cell non-Hodgkin's lymphoma (NHL). - An Examination of Non-Hodgkins Lymphoma By : Morgan Hamilton
Cancer is a life-threatening disease that is prevalent in our time. One of which is known as non-Hodgkins lymphoma or NHL. It is a cancer that affects the lymphatic system and develops in the lymphoid tissue, which contain lymphocytes that are found all over the body. - EntreMed Commences MKC-1 Clinical Trial In Leukemia Patients By : Leukemia News
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced commencement of a Phase 1 study with its clinical-stage drug candidate, MKC-1, in patients with hematological (blood) malignancies. The study will be conducted at the University of Texas MD Anderson Cancer Center in Houston, Texas. - EntreMed Commences MKC-1 Clinical Trial In Leukemia Patients By : Leukemia News
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced commencement of a Phase 1 study with its clinical-stage drug candidate, MKC-1, in patients with hematological (blood) malignancies. - Glivec® Receives Additional EU Approvals For Use In Treating A Rapidly Progressive Form Of Leukemia By : Leukemia News
Novartis has received additional European Union approvals for Glivec® (imatinib) to help patients with a rapidly progressive form of leukemia as well as a hard-to-treat solid cancer tumor. Both are rare and potentially life-threatening diseases with few, if any, approved treatments that have resulted in poor long-term outcomes. - Vaccination Increases Survival In Lymphoma Patients By : Leukemia News
Idiotypic vaccination can increase the survival times of follicular lymphoma patients. - Autoimmune Conditions Linked To Hodgkin Lymphoma Incidence By : Leukemia News
A personal history of systemic autoimmune disease is associated with an increased risk of Hodgkin lymphoma; a family history of some autoimmune conditions may also be associated with increased risk. - New Drug Target Might Sidestep Gleevec Resistance, Jefferson Scientists Show By : Leukemia News
Though enormously successful, the leukemia drug Gleevec has some downsides. Recent studies have linked the drug to heart failure in a small number of patients, and drug resistance continues to be a problem. But now, researchers at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia may have found a new way to sidestep such resistance. - Combination Of High Dose QUADRAMET(R) And Chemotherapy Shows Promise For Treatment Of High-Risk By : Leukemia News
Cytogen Corporation (Nasdaq: CYTO) today announced the publication of new data relating to the Company's QUADRAMET(R) (samarium Sm-153 lexidronam injection) product. - Epstein-Barr Virus' Ability To Form And Sustain Tumors, Clue Found By Researchers By : Leukemia News
Researchers at the University of Wisconsin School of Medicine and Public Health (SMPH) have found a viral target that opens the door for the development of drugs to destroy tumors caused by Epstein-Barr virus (EBV). - Genzyme Begins Phase 3 Pivotal Study Of Clolar(R) In Adult Acute Myelogenous Leukemia By : Leukemia News
Genzyme Corporation (Nasdaq: GENZ) announced today that the first patient has been treated in a new phase 3 clinical trial examining the safety and effectiveness of Clolar(R) (clofarabine) in older patients with acute myelogenous leukemia (AML). This is the first pivotal clinical study of clofarabine in adult patients with AML, and is expected to provide substantial support for expanding the current product label. - Allos Therapeutics Initiates Pivotal Phase 2 Study Of PDX In Patients With Peripheral T-cell By : Leukemia News
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced enrollment of the first patient in PROPEL, a pivotal multi-center Phase 2 study of the Company's unique next generation antifolate PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). - SGX Pharmaceuticals Discontinues Phase II/III Clinical Trial Of Troxatyl In Third-Line Acute By : Leukemia News
SGX Pharmaceuticals, Inc. (Nasdaq: SGXP) announced today that it has discontinued the Phase II/III clinical trial of Troxatyl(TM) as a third-line treatment for patients suffering from acute myelogenous leukemia (AML), based upon the recommendation of the study's independent data and safety monitoring board (DSMB). The DSMB found that the study response rates were unlikely to provide evidence of a treatment benefit as a third-line treatment for patients with AML. - New Strain Of Mice Mimics Chronic Leukemia And Will Aid Drug Development By : Leukemia News
A study by cancer researchers here reveals that a new strain of mice offers the first real animal model for an incurable form of chronic leukemia and should greatly aid the development of new drugs for the disease. - CuraGen And TopoTarget Announce Southwest Oncology Group Opens New Lymphoma Trial With PXD101 By : Leukemia News
CuraGen Corporation (Nasdaq: CRGN) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) today announced the Southwest Oncology Group, a national clinical trials cooperative group, has just opened a Phase II clinical trial to test the effects of a new investigational agent on aggressive B-cell lymphoma. - Hana Biosciences Initiates Marqibo(R) Phase II Clinical Trial in Relapsed By : Health News
Hana Biosciences (NASDAQ:HNAB):
-- Trial Represents First Stage of Registration Program for Targeted Chemotherapy Agent
-- Multinational, Multicenter Phase III Randomized Trial in ALL to Commence before Year-End 2006
|
